10-QPeriod: Q3 FY2025

Medtronic plc Quarterly Report for Q3 Ended Jan 24, 2025

Filed February 25, 2025For Securities:MDT

Summary

Medtronic plc reported solid financial results for the nine months ended January 24, 2025, with net sales reaching $24.6 billion, a 4% increase compared to the prior year, driven by growth across most business segments, particularly in Cardiac Rhythm & Heart Failure, Diabetes, and Neuromodulation. Diluted earnings per share (EPS) for the nine-month period were $2.79, a significant increase from $2.27 in the prior year, reflecting improved profitability. The company generated strong operating cash flow of $4.5 billion and free cash flow of $3.1 billion for the nine months, underscoring its financial health and ability to fund operations and shareholder returns. Medtronic's liquidity remains robust, with $1.2 billion in cash and cash equivalents and $6.7 billion in current investments as of January 24, 2025. Key operational highlights include continued strong performance in the Cardiovascular and Neuroscience portfolios, with notable growth in specific product lines such as the MiniMed 780G insulin pump system and the Inceptiv spinal cord stimulator. The company also reported progress in new product adoption, such as the Evolut FX+ TAVR system and the Aurora Extravascular ICD system. While facing some headwinds in Medical Surgical segments, the overall sales trajectory and profitability improvements indicate a positive operational performance. Investors should monitor Medtronic's ongoing product innovation, geographic expansion, and its ability to navigate competitive pressures and macroeconomic factors, as highlighted in the MD&A, which could influence future performance.

Financial Highlights

54 data points
Beta

Revenue

$8.29B

66.5% Gross Margin

Net Income

$1.30B

15.7% Net Margin

EPS (Diluted)

$1.01

Total Assets

$89.97B

Cash & Equivalents

$1.24B

Free Cash Flow

$2.10B

Financial Statements
Beta
Revenue$8.29B
Cost of Revenue$2.78B
Gross Profit$5.51B
SG&A Expenses$2.72B
Operating Income$1.65B
Net Income$1.30B
EPS (Basic)$1.01
EPS (Diluted)$1.01
Shares Outstanding (Basic)1.28B
Shares Outstanding (Diluted)1.29B

Key Highlights

  • 1Net sales increased by 4% to $24.6 billion for the nine months ended January 24, 2025, driven by broad-based growth across key segments.
  • 2Diluted earnings per share (EPS) rose to $2.79 for the nine months ended January 24, 2025, up from $2.27 in the prior year, indicating improved profitability.
  • 3Operating cash flow strengthened to $4.5 billion for the nine months ended January 24, 2025, with free cash flow reaching $3.1 billion.
  • 4The Cardiovascular segment saw a 5% increase in net sales for the nine months, driven by Cardiac Ablation Solutions, Structural Heart, and Cardiac Pacing Therapies.
  • 5The Neuroscience segment reported a 5% increase in net sales for the nine months, primarily due to growth in Neuromodulation, Spine and Biologics, and Neurosurgery.
  • 6The Diabetes segment experienced an 11% increase in net sales for the nine months, attributed to strong adoption of the MiniMed 780G AID system and international CGM growth.
  • 7Medtronic maintained a strong liquidity position with $1.2 billion in cash and cash equivalents and $6.7 billion in current investments as of January 24, 2025.

Frequently Asked Questions

Medtronic reported a 4% increase in net sales to $24.6 billion for the nine months ended January 24, 2025. This growth was primarily driven by strong performance in Cardiac Ablation Solutions, Structural Heart, Cardiac Pacing Therapies, Neuromodulation, and the MiniMed 780G AID system in the Diabetes segment.

Profitability improved significantly. Diluted earnings per share (EPS) for the nine months ended January 24, 2025, increased to $2.79 from $2.27 in the prior year. This improvement reflects strong revenue growth and effective cost management.

Medtronic maintains a strong liquidity position, with $1.2 billion in cash and cash equivalents and $6.7 billion in current investments as of January 24, 2025. The company believes its balance sheet and liquidity sources are sufficient to meet foreseeable operating needs and capital allocation strategies.

The company is involved in various legal actions, including product liability, intellectual property, and commercial disputes. While specific charges were noted for certain litigation ($22 million and $104 million for the three and nine months ended January 24, 2025, respectively), Medtronic believes the ultimate resolution of most matters is not expected to have a material adverse impact, although uncertainties remain. The company also faces potential impacts from Italian payback legislation and ongoing tax audits.